“The increase was primarily driven by an increase in cash collected from customers due to an increase in sales and decrease in cash paid for taxes and certain litigation payments, partially offset by an increase in cash paid to suppliers and other vendors.”10-Q · Sep 3, 2026 ↗
Medtronic plc
MDT
You’ve read what changed. Here’s whether the market is confirming it.
Market read
Medtronic plc's current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 30 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 30 directly disclosed connections are confirming.
- MDT's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if MDT's group or a disclosed connection begins moving with it.
Research brief
The story so far
No new filing conclusion is available. 0 of 30 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 30 directly disclosed connections are confirming.
No thresholded supportive filing evidence is available yet.
No thresholded adverse filing evidence is available yet.
- MDT's market-adjusted activity becomes unusual and at least one connected name confirms.
Company research
Understand the business, not just the ticker
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
- Which operating variable is changing?
- Is that change durable, cyclical or one-off?
- What evidence would disprove the current interpretation?
- Latest annual revenue changed +8.4% year over year.
- Operating cash flow covered net income at 1.53x in the latest annual period.
- Foreign exchange has repeated favorable evidence across 4 filings.
- Product pipeline and R&D has repeated favorable evidence across 4 filings.
No qualifying adverse evidence was identified; that is not proof there is no downside.
- P/E is 31% above the available filing-peer median; determine whether growth and quality justify the difference.
- EV/sales is 18% below the available filing-peer median; determine whether growth and quality justify the difference.
Price as of Sep 10, 2026
91.64Reported annual revenue and per-share history. This is accounting history, not a forecast.
What management says matters
Persistent and emerging business drivers
“The increase in total debt was primarily driven by the increase in short-term borrowings, partially offset by the impact of foreign exchange rates on our foreign currency denominated debt.”10-Q · Sep 3, 2026 ↗
“For the three months ended July 31, 2026, the change in other operating expense (income), net was largely driven by a reduction in income relating to our research and development funding arrangements, partially offset by the net impact of currency remeasureme…”10-Q · Sep 3, 2026 ↗
“The increase in total debt was primarily driven by the increase in short-term borrowings, partially offset by the impact of foreign exchange rates on our foreign currency denominated debt.”10-Q · Sep 3, 2026 ↗
Valuation discipline
Descriptive valuation snapshot
Price/sales 3.2× · EV/sales 3.2×. Comparisons use only industry-matched filing peers.
Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.
Price action
How the market is pricing the story
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 11 Sept, 09:30 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
No sourced recent-development timeline yet
Jodie has not returned a relevant primary source or news item for MDT. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Reported financial figures are not available yet
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
No comparable filing assessment is available yet
Jodie has not yet found a suitable current-versus-prior filing comparison for MDT. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
The relationships behind MDT
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
ABTAbbott LaboratoriespartnerFeb 24, 2026 ▾
“Our ability to meet growing demand for our existing products and to successfully develop, obtain regulatory approval, manufacture and commercialize the products within our pipeline, including our partnership with Abbott to expand CGM options for people living…”
DVADaVita Inc.partnerJun 18, 2026 ▾
“This sale was part of an agreement between Medtronic and DaVita to form a new, independent kidney care-focused medical device company (“Mozarc Medical” or "Mozarc") with equal equity ownership.”
Depended on by
AORTArtivion, Inc.competitorMay 8, 2026 ▾
“On-X heart valves compete primarily with mechanical valves from Abbott Laboratories, Medtronic, plc.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 32 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
MDT is currently a Participant in the organic co-movement group Mixed Multi-Sector. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for MDT; it is not active in the latest market snapshot.
Context history
Theme membership history
No durable theme membership has been observed for this name yet.